A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer

Phase 1 Active not recruiting 258 enrolled Nalo Therapeutics Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of NX-019 and preliminary efficacy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutant cancer.

Timeline

Start: 2022-10-05
Primary completion: 2025-06-01
Completion: 2025-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NX-019	Unknown	—	Oral

Indications

No indication recorded.